Krystal Biotech

Recent news

• Rating change
  Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386
  Market Newswire · 2026/8/4
• Rating change
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $361
  Market Newswire · 2026/6/16
• Rating change
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $364
  Market Newswire · 2026/6/1
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Krystal Biotech (KRYS), AbbVie (ABBV) and Tempus AI, Inc. Class A (TEM)
  TipRanks · 2026/6/1
• Rating change
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Cuts Target Price to $392
  Market Newswire · 2026/8/4
• BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400
  Market Newswire · 2026/9/21
• Rating change
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $396
  Market Newswire · 2026/7/14
• Jefferies Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $474
  Market Newswire · 2026/7/13
• Rating change
  RBC Capital Initiates Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $400
  Market Newswire · 2026/8/15
• Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock
  Market Newswire · 2026/8/15
• Rating change
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating
  Market Newswire · 2026/5/14
• Rating change
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $361
  Market Newswire · 2026/8/4
• Rating change
  BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Announces Target Price $364
  Market Newswire · 2026/5/22
• Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441
  Market Newswire · 2026/9/24
• Rating change
  TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $403
  Market Newswire · 2026/8/4
• Rating change
  William Blair Maintains Krystal Biotech(KRYS.US) With Buy Rating
  Market Newswire · 2026/8/4
• Rating change
  TD Cowen Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $403
  Market Newswire · 2026/6/18
• Rating change
  Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating
  Market Newswire · 2026/8/12
• Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock
  Market Newswire · 2026/9/5
• Rating change
  H.C. Wainwright Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $310
  Market Newswire · 2026/6/1

Headlines are aggregated automatically and are not independently verified or edited by our team.